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OBJECTIVES: Theoretically, willingness to pay (WTP) for quality adjusted life years 
(QALY) can differ between social and personal preferences and between ex-ante 
and ex-post settings. However, empirical investigation for these differences is still 
lacking. In Japan, setting the threshold has been controversial during the process 
implementing HTA, started from 2016 as a pilot. Our objective is to estimate WTP 
values with different perspectives and contexts. METHODS: We performed a 
web-survey to measure WTP for one additional QALY in individual, social, and 
social inclusive perspectives. In addition, two contexts (ex ante and ex post) at the 
end-of-life (EoL) were measured. Double-bound dichotomous choices for hypo-
thetical choice setting for drugs, which payers and beneficiaries are varied by 
scenarios, were adopted to this research. 1,030 respondents, representative of 
the Japan population, were sampled from an online panel and answered one of 
10 questionnaire decks, which varied for the amount of QALY losses (2 levels) 
and the starting point of WTP (5 levels). RESULTS: WTP per QALY varies signifi-
cantly, according to three perspectives, different health states and two contexts 
of EoL. WTP in non-EoL setting can be changed two times. WTP in EoL setting 
differs substantially, too. CONCLUSIONS: WTP values were sensitive to different 
perspectives, uncertainty in the future, health states and incomes. The use of uni-
form threshold needs to be careful in policy settings, because the fixed threshold 
may not reflect diverse preferences based on different situations of each 
individual.
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OBJECTIVES: Cost-utility analysis requires cost effectiveness threshold to inter-
prete the acceptability of the cost effectiveness ratio. Cost effectiveness threshold 
is setting specific based on each country contex. This study aimed to estimate 
the WTP per QALY as cost-effectiveness threshold for pharmacoeconomic study 
in Indonesia. METHODS: A pilot study for estimation of WTP per QALY was con-
ducted using community-based survey in Yogyakarta Province. A sample size of 
1500 general population respondents was selected using stratified sampling. Three 
versions of instrument including version of moderate disease, terminal disease, 
and life saving treatment were employed. The instruments which were based 
on hypothetical scenario consisted of three parts, namely socio-demographic 
information, utility elicitation, and WTP elicitation. RESULTS: There was sig-
nificant different of utility gain among moderate disease, terminal illnes, and 
life saving treatment. Utility gain measured with EQ-5D index score in moder-
ate illness, terminal illnes, and life saving were 0.539; 0.883, and 0.945, respec-
tively. There was significant different of the average of maximum amounts of 
willingness to pay moderate disease, terminal illnes, and life saving treatment 
which were IDR 11,478,153; IDR 31,511,155; IDR 76,247,305 for moderate disease, 
terminal illnes, and life saving treatment, respectively. Finally, there was signifi-
cant different of the average of WTP per QALY among moderate disease, terminal 
illness, and life saving treatment, which were IDR 34,702,926 (SD= 61,514,456); 
IDR 194,976,141 (SD= 350,974,703); and IDR 192,514,839 (SD= 301,386,928), respec-
tively. The values of WTP per QALY ranged from 1 – 4 times of GDP per capita of 
Indonesia. CONCLUSIONS: This study gives insight of the method and estimated 
value of WTP per QALY as cost effectiveness threshold in Indonesia. Further study 
should be conducted to estimate WTP per QALY for larger and various population 
based on geographical and sociodemographic characteristics in Indonesia and 
from patients perspective.
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OBJECTIVES: To generate estimates of willingness-to-pay (WTP) to avoid foodborne 
illness (FBI), specifically two acute (gastrointestinal (GI) and flu-like illness) and 
four chronic (irritable bowel syndrome (IBS), Guillian-Barre syndrome, reactive 
arthritis, and haemolytic uraemic syndrome (HUS)) illnesses. METHODS: A dis-
crete choice experiment was designed. The vignettes and attributes developed 
were based on the literature and clinician input. Respondents were randomised 
to complete 20 DCE tasks for two different illnesses, with mild and severe health 
states, and asked to select their preferred choice set from one of two options. 
Attributes related to work participation, such as the ability to work and availability 
of sick leave were included, as were costs of treatment to alleviate symptoms, and 
illness duration. Choices were modelled using conditional logit regression and 
adjusted for condition severity. RESULTS: A total of 1,918 respondents completed 
the survey. The WTP to avoid a severe illness was higher than a mild illness. The 
marginal WTP (MWTP) was affected by paid sick leave: for example, the MWTP to 
avoid mild GI increased by $139 without paid sick leave. The MWTP to avoid a mild 
chronic illness for one year, ranged from $344 for IBS to $901 for HUS, and when 
severe ranged from $964 for IBS to $1,620 for HUS. There was a substantial increase 
in the MWTP to avoid all the chronic conditions when the ability to work reduced 
and sick leave was not paid, ranging from $9,906 for severe IBS to $11,652 for severe 
HUS. CONCLUSIONS: The explicit inclusion of factors that reflect productivity and 
compensation to workers influenced the WTP to avoid a range of FBIs for both 
acute and chronic conditions, and across both mild and severe conditions. The 
results indicate that both the severity of the FBI and consideration of the effect 
on productivity were important factors.
“Chronic Hepatitis” in Chinese periodical full-text database, CNKI, Wanfang, CQVIP 
and China Biomedical Literature Database. The search period is as of December 2017 
(no starting date). Finally, there were 50 valid literature were selected. RESULTS: The 
main diseases of concern were chronic hepatitis B (30, 60%) and cirrhosis (12, 24%). 
There were 32 articles (64%) analyzed the development process and applicability of 
TCM QOL scale,11 (22%) were single evaluation of the literature on QOL of patients 
during studies conducted, and only 7 (14%) evaluated the impact of interventions on 
patient QOL. In the aspect of using the QOL scale, 35 articles (70%) used only the QOL 
scale based on TCM theory,7 articles (14%) also used SF-36, 6 articles (12%) addition-
ally used the CLDQ scale, and only 2 articles (4%) used mental health measurement 
scale(SAS, SDS) simultaneously. These articles involved 27 QOL scales based on 
TCM theory, chronic hepatitis B(16, 59.26%), cirrhosis of liver (8, 29.63%) and chronic 
hepatitis C (3, 11.11%). TCM symptom scales (28 times, 56%) have higher application 
frequency, the next are The Chronic Hepatitis B Patients PRO scale (TCHB - PRO) 
(5 times, 10%), TCM liver disease PRO scale (4 times, 8%), Chronic Hepatitis B Chinese 
characteristics PRO scale (3 times, 6%), etc. CONCLUSIONS: The QOL scale developed 
on the basis of TCM theory of liver disease has gradually increased. But there are still 
many problems, such as not so standardized scale development program, mainly 
TCM syndromes, and less involved psychological and social support. The existing 
scales are mostly non-preference-based scales that could not be used for cost-utility 
analysis (CUA) of different interventions.
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OBJECTIVES: To analyze the application status of health-related quality of life scale 
(HRQOL) in the field of chronic hepatitis in China, and to provide references for the 
selection of HRQOL scale. METHODS: The study was a retrospective analysis, as of 
December 2016, a total of 233 valid papers published in academic journals in China. 
The 12 indicators were extracted from the literature for statistical analysis (includ-
ing basic information, research content, quality of life (QOL) scales, etc). RESULTS: 
A total of 173 articles (74.25%) evaluated the QOL of patients’ with chronic hepatitis 
B, then the liver cirrhosis (33 articles, 14.16%). 103 articles (44.21%) were single evalu-
ations of patients’ QOL during the study period, and 130 articles (55.79%) evaluated 
the impact of single or multiple interventions on patients’ QOL. Scale application 
aspects, 157 articles (67.38%) only choose single QOL questionnaire to evaluate the 
patient’s QOL, universal scale (124, 78.98%), special scale (17, 10.83%), mental health 
measurement scale (16, 10.19%). 70 (30.04%) papers also used two or more kinds 
of scales to evaluate the patients’ QOL. Among them, if a single scale was chosen, 
the researchers chose SF-36 (83 papers, 66.94%), CLDQ (8 papers, 47.06%) and SAS 
combined with SDS scale (8 papers, 50%). If two or more types of scales were chosen 
simultaneously, the researchers chose SF-36/WHOQOL-BREF which combined with 
CLDQ scale (13 articles, 18.57%), SF-36/WHOQOL-BREF/GQOLI-74/CLDQ combined 
with SAS and SDS scale (19 articles, 27.14%). In addition, a few papers still use QLICD 
(5 articles) and QLICD-CH (3 articles). CONCLUSIONS: There are still some problems 
in the HRQOL assessment of chronic hepatitis in China. For example, most research-
ers only chose universal scale to evaluate QOL rather than chose different types of 
scales. The scales that are developed by foreign institutes or researchers are chosen 
more frequently than domestic ones, etc.
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OBJECTIVES: This study sought to determine the willingness of individuals to pay 
(WTP) for a quality-adjusted life year (QALY) from the individual perspective in 
Taiwan. METHODS: This study conducted a computer-assisted telephone interview 
(CATI) survey, based on EQ-5D, of a nationally representative sample of 1217 adults 
aged 20 and older in 2013. Respondents were asked to rank two scenarios of health 
state (23 pairs in total) according to preference. They were also asked how much 
they would be willing to pay to attain a given improvement in health status. Those 
who are unable to answer this open question would then enter an iterative bidding 
procedure to determine approximate WTP values. WTP per QALY was obtained by 
dividing WTP by the difference between the QALY of two health states. We also 
evaluated the effects of the following factors on the WTP/QALY ratio: gender, age, 
education, marital status, occupation, monthly household income, region of resi-
dence, and self-reported health score obtained using the GEE model. RESULTS: Most 
of the participants were female (54.48%), 20 to 39 years old (30.37%) (mean age of 47), 
with a college or higher education (35.77%), married (73.25%), of a level 4 occupa-
tion (38.92%), with moderate monthly household income (38.33%), urban dwelling 
(59.98%), a mean self-reported health score of 72.48 and without disease (73.05%). 
The mean WTP per QALY was USD 32,833 (1 USD= 29.77 NTD in 2013) based on VAS 
valuations, and the mean WTP per QALY was USD 45,085, based on UK EQ-5D tariffs. 
Occupation, monthly household income, and region of residence were shown to be 
significant factors associated with the WTP per QALY ratio. CONCLUSIONS: The 
WTP per QALY ratios estimated in this study were approximately 1.57-2.15 times 
the 2013 per capita GDP in Taiwan. This result provides a reference to guide policy-
makers in the setting of priorities for health insurance coverage.
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from payer and societal perspectives. CONCLUSIONS: Prescribing extended-release 
phenytoin tended to have the lowest total budget impact compared with the other 2 
scenarios. Policy recommendation developed from this research would help solving 
antiepileptic drug issue in Thailand.
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OBJECTIVES: To prevent hemolytic disease of the fetus and newborn, routine ante-
natal care in many countries involves RhD immunoglobulin (anti-D) being offered 
to all RhD negative pregnant women. Recent advances in non-invasive cell-free fetal 
DNA testing of the RHD gene has made targeted administration of anti-D possible 
to women with a baby predicted to be RhD positive. Our objective was to under-
take a cost-effectiveness analysis and budget impact analysis of non-invasive fetal 
RHD genotyping to target pregnant women for antenatal anti-D prophylaxis ther-
apy. METHODS: A decision-analytic model was constructed to compare RHD testing 
and targeted anti-D prophylaxis, with current universal anti-D prophylaxis among 
pregnant women with RhD negative blood type. Model estimates were derived 
from national perinatal statistics, published literature, donor program records and 
national cost sources. One-way sensitivity analyses addressed the uncertainty of 
variables on the main findings. RESULTS: The unit cost for RHD genotyping was 
estimated at AU$45.48 (US$31.84). The ‘mean cost per healthy baby’ was AU$7,495 
(US$5,247) for universal prophylaxis and AU$7,471(US$5,230) for targeted prophy-
laxis. The findings were sensitive to the unit costs of anti-D 625 IU (AU$59-$88)
(US$41-62), the genetic test (AU$36-$55)(US$25-39) and, packaging/transport costs 
of the samples for testing (AU$15-40, US$11-28 per sample). With RHD genotyping, 
13,938 women would avoid antenatal anti-D prophylaxis at a total cost-savings 
to the National Blood Authority of AU$2.1 million (US$1.5 million) per year. To the 
health system, net cost savings of AU$159,701 (US$111,791) per year (0.05%) were 
predicted for total healthcare costs. CONCLUSIONS: Routine RHD genotyping for 
RhD negative women during pregnancy would produce substantial cost-savings for 
the Australian National Blood Authority while being cost-neutral to the whole health 
system. Notwithstanding the vulnerable supply of donor plasma and other ethical 
and health concerns, RHD genotyping is an economically sound option for Australia.
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OBJECTIVES: Analysis of the economic impact, usage and cost of the different thera-
pies prescribed to Epilepsy patients in the Valencian Community, Spain. METHODS: 
The patients were indentified through the ATC code N03A, in the database of the 
Valencian Community where all the prescribed medication information/data is 
kept, for the 2014. In the analysis, the medication is classified by therapies mono-
therapy or combination, and by generation of the active drug. RESULTS: There were 
indentified 26,972 patients that consumed at least one AED, this represents 5,7/ 1000 
inhabitants. From these patients, the majority was prescribed second generation 
AEDs (63.6%), as monotherapy or in combination. The cost of these second genera-
tion AEDs was 61.8% of the total costs of AEDs. The Leviracetam (LVT) was the most 
prescribed AED, a 31.8% of the patients in total, and not taking into account the 
therapy applied. The prescription of this medication was 43.6% of the total cost 
of AEDs prescribed. Additionally, the 21.4 % of epileptic patients were prescribed 
Sodium Valproate (SV), either in mono or combination therapy, resulting as a 4.2% of 
the total costs. Lastly, analysing the third-generation AEDs prescribed, were 12.8% of 
the total patients, either in mono or combination therapy. These represented 27.3 % 
of the total costs, being lacosamide (LCM) the most prescribed. CONCLUSIONS: The 
second generation AEDs continue to be the most prescribed, and with higher costs, 
being Leviracetam (LVT) the therapy most elected for the treatment of epilepsy. More 
studies are being conducted to follow-up the trend.
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OBJECTIVES: PDSAFE is an individually-tailored, physiotherapist delivered balance, 
strength and strategy training programme aiming to prevent falls among people 
with Parkinson’s (PwP). The objective of this study was to evaluate the cost-effec-
tiveness of PDSAFE compared with usual care for PwP who are at a higher risk of 
falling from a UK NHS and Personal Social Service (PSS) perspective. METHODS: 
238 PwP were randomised to the intervention group, receiving 12 physiotherapy 
sessions over 6-months; and 236 to the control group, receiving usual care (PDSAFE 
trial: ISRCTN48152791). Resource use and EQ-5D-3L data were collected at base-
line, 3 months, 6 month, and 12 months. Missing data were imputed with mul-
tiple imputation. Generalized linear models were used to predict differences in 
costs and QALYs adjusting for baseline utility, baseline resource use, and the key 
demographics and medical history variables. A 1000-iteration Bootstrapping was 
conducted to investigate the uncertainty surrounding the Incremental cost effec-
tiveness ratio (ICER) estimate. RESULTS: At six months, the intervention group is 
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OBJECTIVES: Some studies have illustrated that the relative efficacy and safety of 
widely used drugs can vary over time substantially. Possible influencers may include 
changes in population characteristics, inclusion or exclusion criteria such as patients 
with prior exposure to the active reference, or variation in the placebo response. 
Sumatriptan was considered as an illustrative case to examine this phenomenon, 
as it has steadily been used as a reference treatment over time for acute migraine 
episodes. METHODS: A systematic literature review of randomized controlled trials 
(RCTs) of adults suffering from acute migraine episodes evaluating oral sumatriptan 
versus placebo was performed in Medline for the period from before and shortly after 
approval (1991) to the following 15 years. Meta-analyses were performed using the 
inverse-variance weighted average method to estimate the odds-ratios of the occur-
rence of pain-free at 2 hours and of any adverse event, by time period. RESULTS: Out 
of the 67 RCTs identified, pain-free at 2 hours and any adverse event outcomes were 
reported in 25 and 28 studies, respectively. The odds ratio (95% CI) for the occurrence 
of pain-free for sumatriptan versus placebo was first evaluated at 3.13 (1.67-5.86) with 
meta-analysis based on the first RCTs assessing sumatriptan before or shortly after 
approval (1991-1994) and increased up to 4.14 (3.67-4.67) using also RCT data post-
approval (1995-2006). No specific variation was observed in the relative tolerability 
effect of sumatriptan over placebo over time. CONCLUSIONS: This research provides 
new evidence that the relative effect of widely used drugs such as sumatriptan can 
evolve over time substantially. This issue is particularly problematic when network 
meta-analysis or indirect comparisons are subsequently performed to evaluate the 
potential of a new drug, compared to widely prescribed older drugs. Assessment of 
this effect should be evaluated when making comparative analyses.
PND2
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OBJECTIVES: To systematically review and evaluate the clinical effectiveness of TCM 
in AD patients. METHODS: Three electronic databases (Medline, Cochrane Library 
and China National Knowledge Infrastructure) were searched for clinical studies 
investigating the efficacy of TCM or TCM and western medicine in AD patients from 
1 January 2010 to 10 March 2016. Meta-analyses were conducted for studies with 
sufficiently homogenous outcome measure and study designs using RevMan 5.3, 
with results reported as relative risk (RR). 15 articles involving 1124 AD patients 
met the selection criteria and were analyzed. RESULTS: When pooled together, 
regardless of adding onto western medicine or alone, TCM was more effective than 
western medicine alone (RR, 1.20; 95%CI:1.14-1.28). For subgroup analyses of TCM vs. 
western medicine, TCM again produced significantly better outcome compared 
with western medicine (RR, 1.21; 95%CI:1.11-1.31).TCM plus western medicine 
interventions also showed statistically significant better effects compared with the 
western medicine alone (RR, 1.20; 95%CI:1.10-1.31). CONCLUSIONS: This systematic 
review suggested that managing AD with TCM or TCM and Western medicine com-
bination are more effective than Western medicine alone. However, limitations of 
method and quality in the included trials would require further long-term clinical 
studies with larger sample size to confirm the results.
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OBJECTIVES: The availability of antiepileptic drugs per hospital and the incor-
rect drug administration are the major epileptic treatment problems, especially 
for phenytoin as it may cause uncontrolled seizures or adverse events. This study 
estimated the budget impact of extended-release phenytoin capsule compared with 
immediate-release phenytoin capsule for epilepsy patients in Thailand. METHODS: 
Decision tree model was developed to estimate total budget impact for 3 scenarios; 
scenario 1: All prescriptions were original, scenario 2: All prescriptions were generic, and 
scenario 3: All prescriptions were based on the current phenytoin market share. Thai epi-
lepsy epidemiology, consequences of uncontrolled seizure and costs were derived from 
the systematic review literatures and Thai hospital database. All costs were adjusted for 
the year 2017 and analyzed from payer and societal perspectives. One way sensitivity 
analysis was performed. RESULTS: Of 95,613 patients receiving phenytoin, there were 
57,368 cases controlled epilepsy and 38,245 cases uncontrolled epilepsy which caused 
229,471 seizures/year. Total scenario 1 budget was 1,476,131,325 to 1,639,184,886 baht 
from payer and societal perspectives. For scenario 2, total controlled and uncontrolled 
cases were similar to scenario 1. Either uncontrolled patients taking drug once daily (OD) 
or 3 times/day (TID) would result to seizures 128,504 times/year and 563,886 times/year, 
respectively. Total scenario 2 budget was 3,405,019,828 to 3,651,446,719 baht from payer 
and societal perspectives. Scenario 3 was estimated from 73% of original share (69,797 
cases) and 27% of generic share (25,815 cases). Seizures occurred 167,514 times/year in 
original group, 34,696 times/year in generic TID group and 152,249 times/year in generic 
OD group which accounted for total budget impact 1,996,931,213 to 2,182,495,573 baht 
